Human studies have shown that CJC-1295 raises IGF-1 by roughly 1.5-3 times baseline after a single dose, lasting for over a week. However, there is no established clinical monitoring protocol, „optimal range,” or blood testing schedule specifically validated for individuals using CJC-1295 or ipamorelin. A blood test for IGF-1 itself is a standard, well-established clinical tool. It has simply not been formally paired with monitoring guidelines for these two peptides.
To what extent do CJC-1295 and ipamorelin increase IGF-1?
IGF-1 is a hormone that the liver produces in response to growth hormone signals. It is often used as a marker for assessing how active the growth hormone system truly is. The most pronounced quantitative data regarding IGF-1 increases comes from a landmark human study concerning CJC-1295. Healthy adult volunteers were given single, escalating doses under controlled clinical conditions. Researchers measured a 1.5 to threefold increase in IGF-1 above baseline after a single dose. This elevation lasted for nine to eleven days [1]. This IGF-1 response occurred after an initial increase in growth hormone itself. Growth hormone increased more dramatically – two to tenfold. However, it lasted for a shorter period, six days or longer. This helps explain why IGF-1 is generally considered a more useful marker for tracking sustained biological activity of this compound. It rises more gradually in the liver in response to growth hormone stimulation and then remains elevated for longer than the pulse of growth hormone that triggered it [1].
When CJC-1295 was administered repeatedly over several weeks in the same study, IGF-1 remained above baseline for up to 28 days. The study authors specifically described evidence of a cumulative effect. This means that the elevation built up with each subsequent dose rather than simply resetting to baseline between injections [1].
It is important to note something here. These multiple growth factor numbers come from one specific research population: healthy adults aged 21–61, using the specific doses tested (most notably 30 and 60 micrograms per kilogram). No equivalent, dedicated human study measuring IGF-1 response to ipamorelin alone or both compounds together has been identified in the literature reviewed for this paper. This means the IGF-1 numbers above should be understood as describing CJC-1295 specifically, not as the result of a combined protocol.
How long do CJC-1295 and ipamorelin take to increase IGF-1?
Based on the same research data, the IGF-1 elevation schedule follows a fairly predictable pattern after a single dose. Growth hormone rises first, within hours. IGF-1 follows with a delay, as it must be produced by the liver in response to the growth hormone signal, rather than being released instantaneously. It then reaches its own elevated plateau, which lasts for nine to eleven days after just one injection [1]. For anyone using a repeated weekly or bi-weekly schedule, similar to the pattern tested in the original studies, achieving the kind of sustained, cumulative 28-day IGF-1 elevation documented in this study would be expected to require multiple doses within that same multi-week period – not just a single injection [1].
It's worth reiterating that this timeline reflects blood hormone measurements taken in a specific, monitored clinical trial. It is not the same as a guide to when someone might notice a subjective or visible change. No study identified in this research series tracked physical or symptomatic outcomes alongside blood IGF-1 measurements.
Monitoring IGF-1 and blood tests with CJC-1295 and Ipamorelin
A simple blood test for IGF-1 is a well-established, standard clinical laboratory tool. It is regularly used in mainstream endocrinology to help diagnose conditions such as growth hormone deficiency and acromegaly, a condition of chronic growth hormone excess. It is also used to monitor patients on legitimate, prescribed growth hormone replacement therapy. This part is well-established, everyday clinical practice – nothing specific to CJC-1295. What does not exist is a validated monitoring schedule, testing frequency, or an „optimal” or „safe” target IGF-1 range specifically established for individuals using CJC-1295 or ipamorelin outside of a formal clinical trial or prescribed medical context. These compounds have not gone through the regulatory approval process that typically produces such standardized monitoring guidelines.
This has particular significance, concerning the worry about IGF-1 being „too high.” As discussed in an earlier article in this series concerning cancer risk, IGF-1 is recognized in mainstream endocrinology as having growth-stimulating, i.e., mitogenic, effects on cells. A 2026 scientific review covering performance-enhancing peptides within the growth hormone–IGF-1 axis specifically proposed that clinicians develop structured frameworks for history taking of exposure and symptom assessment in patients using these unregulated compounds. This proposal exists precisely because standard, formalized guidelines for the interpretation of laboratory results in this particular context do not yet exist [2].
In practical terms, this means something significant. If someone using these compounds were to actually get a blood test for IGF-1, significant interpretation of the result is not something this article can do. Deciding whether a given number reflects an expected, non-concerning response or a level requiring attention requires more than a general reference. No validated reference range for „acceptable” self-administered IGF-1 elevation has been established. That kind of interpretation requires a licensed healthcare professional who knows the individual's full clinical picture—ideally someone with endocrinology experience—not a general online reference range.
Limitations of current evidence
The above described growth multiplication and schedule data for IGF-1 are well-documented specifically for CJC-1295, from a small but real clinical study on humans [1].
What's missing is any equivalent data for ipamorelin alone or both compounds together. Perhaps more importantly for anyone actually testing their own levels, there is no established, validated monitoring protocol, testing interval, or interpretative safety range specific to the off-label use of CJC-1295 or ipamorelin. This leaves a real gap between accessing laboratory testing and knowing how to safely interpret it in this context.
Disclaimer
This content is for educational and informational purposes only and should not be construed as medical advice, diagnosis, or guidance for interpreting laboratory results. CJC-1295 and ipamorelin remain research compounds and are not approved by the FDA or European Medicines Agency for any medical use, whether used individually or in combination. There is no validated monitoring schedule or safe reference range for IGF-1 for individuals using these compounds outside of a formal clinical trial or prescribed medical context.
References
Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
[2] Dominikowski, A., Rękoś, Z., Olejarz, M., Szczepanek-Parulska, E., Domin, R., & Ruchała, M. (2026). The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: Bridging the gap between clinical evidence and patient self-administration. Frontiers in Endocrinology, 17, Article 1822475. https://doi.org/10.3389/fendo.2026.1822475